Richel Liu
Founder and CEO @ Rimonci Capital
Beijing, China
Richel Liu is a Founder and CEO of Rimonci Capital. She attended Xi'an University of Technology.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Richel Liu invests in
Stages Richel Liu invests in
Countries Richel Liu invests in
Investment Focus
Industry
- Medical Device 4 (67%)
- Health Care 3 (50%)
- Laser 1 (17%)
- Eyewear 1 (17%)
- Medical 1 (17%)
Stage
- Series A 3 (50%)
- Seed 1 (17%)
- Series B 1 (17%)
- Series C 1 (17%)
Country
- Israel 3 (50%)
- France 1 (17%)
- United States 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
TECLens
|
TECLens is creating a crosslinking technology that may accurately fix vision issues in healthy eyes as well as treat keratoconus. It provides patients with presbyopia with the ability to regain their ability to read at a distance, controls children's progressive myopia, corrects adult vision problems like hyperopia and low-order myopia, andmore. | $9.3M / Series A / Feb 11, 2025 | |
Laclarée
|
Laclarée develops a pair of adaptive eyeglasses for presbyopia. Its patented technology allows the eyeglasses to adapt in real-time to the scene viewed by the wearer. This major innovation will help milllions of people 45+ years, who are not satisfied with current solutions (progressive lenses, multiple pairs, etc...). | $3.6M / Seed / Jan 28, 2025 | |
EyeYon
|
EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema.EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer TechnologyIncubator. | $25M / Series C / Mar 15, 2021 | |
BELKIN Vision
|
BELKIN Vision develops a laser device to assist healthcare professionals in treating glaucoma. It offers non-invasive, non-contact, instantaneous, painless, and automated devices offering laser therapy and is aimed at promoting accessibility to first-line drop-less glaucoma care by allowing any ophthalmologist to treat patients. | $12.3M / Series B / Jul 21, 2020 | |
NovaSight
|
NovaSight brings pediatric vision care into the digital age. Our integrated eye-tracking AI based solutions for accurate vision assessment and efficient treatment are specifically designed for the unique needs and attention span of children.NovaSight’s management and scientific advisory board is comprised of experienced executives, researchersand key opinion leaders in the field of pediatric vision care. | $8M / Series A / Jul 13, 2020 | |
|
BELKIN Vision
|
BELKIN Vision develops a laser device to assist healthcare professionals in treating glaucoma. It offers non-invasive, non-contact, instantaneous, painless, and automated devices offering laser therapy and is aimed at promoting accessibility to first-line drop-less glaucoma care by allowing any ophthalmologist to treat patients. | $6.6M / Series A / Jun 05, 2017 |
Co-Investors
About Rimonci Capital
A dedicated to China-Israel cross border investment.
Rimonci Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Richel Liu
Founder and CEO
|
|||
Eddie Wang
COO and Co-Founder
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Richel Liu invest in?
Richel Liu invests primarily in Medical Device, Health Care and Laser startups, most often at Series A and Seed stage. Most of the 6 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Richel Liu last invest?
The most recent investment recorded for Richel Liu closed in Feb 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
